Items Tagged ‘MoAb’

July 5, 2017

Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study


Data from an ongoing clinical study of tisotumab vedotin in solid tumors has demonstrated activity in the treatment of cervical cancer; 11 of 34 evaluable patients achieved a response; with a median time of treatment of 4.9 months and 7 responders are still ongoing or in follow up for progression. The GEN701 study is ongoing […]

View full entry

Tags: Cervical Cancer, MoAb, News, Precision Cancer Medicine, targeted therapy, Tisotumab Vedotin